Physician profile
Max R Johnson
NPI 1679559975
$51,618.90
in general payments reported to CMS, 2019-2025
13 companies · $62.03 in 2025
The $62.03 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,212 · 2020: $76.09 · 2021: $28.55 · 2022: $20K · 2023: $26K · 2024: $264 · 2025: $62.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,430.00 |
| Food and Beverage | $349.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $45,805.00 | 2022-2023 | Hillrom - Retinavue Network, Hillrom - Retinavue 700 Imager |
| Welch Allyn | $5,135.00 | 2019 | |
| Alimera Sciences, INC. | $264.38 | 2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $109.52 | 2019-2022 | |
| Abbvie INC. | $73.79 | 2022 | |
| Astellas Pharma US INC | $62.03 | 2025 | Izervay |
| Allergan, INC. | $58.59 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $33.35 | 2022 | |
| Genentech, INC. | $23.36 | 2023 | Vabysmo, Susvimo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Dutch Ophthalmic, USA | $19.20 | 2022 | |
| Eyepoint US, INC. | $14.45 | 2020 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.